2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary …

J Knuuti, W Wijns, A Saraste, D Capodanno… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the ESC Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Update on the pathophysiology and medical treatment of peripheral artery disease

J Golledge - Nature reviews cardiology, 2022 - nature.com
Approximately 6% of adults worldwide have atherosclerosis and thrombosis of the lower
limb arteries (peripheral artery disease (PAD)) and the prevalence is rising. PAD causes leg …

Rivaroxaban in peripheral artery disease after revascularization

MP Bonaca, RM Bauersachs, SS Anand… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …

2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic …

L Mazzolai, G Teixido-Tura, S Lanzi, V Boc… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin …

P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg… - The Lancet, 2018 - thelancet.com
Background We hypothesised that ticagrelor, in combination with aspirin for 1 month,
followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention …

[HTML][HTML] Global vascular guidelines on the management of chronic limb-threatening ischemia

MS Conte, AW Bradbury, P Kolh, JV White… - European Journal of …, 2019 - Elsevier
Guideline Summary Chronic limb-threatening ischemia (CLTI) is associated with mortality,
amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are …

[PDF][PDF] 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

V Aboyans, JB Ricco, ML Bartelink… - Kardiologia Polska …, 2017 - journals.viamedica.pl
W 2011 roku ESC opublikowało pierwsze wytyczne dotyczące rozpoznawania i leczenia
chorób tętnic obwodowych (PAD)[1]. Ta publikacja wypełniła ważną lukę wśród wytycznych …

[HTML][HTML] Rivaroxaban with or without aspirin in stable cardiovascular disease

JW Eikelboom, SJ Connolly, J Bosch… - … England Journal of …, 2017 - Mass Medical Soc
Background We evaluated whether rivaroxaban alone or in combination with aspirin would
be more effective than aspirin alone for secondary cardiovascular prevention. Methods In …

Sex differences in peripheral artery disease

M Pabon, S Cheng, SE Altin, SS Sethi… - Circulation …, 2022 - Am Heart Assoc
Peripheral artery disease (PAD) is a prevalent condition that confers substantial morbidity
and mortality and remains underdiagnosed as well as undertreated in the overall …

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

SS Anand, J Bosch, JW Eikelboom, SJ Connolly… - The Lancet, 2018 - thelancet.com
Background Patients with peripheral artery disease have an increased risk of cardiovascular
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications …